Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind multicenter study of HL01 versus Humira in moderate-to-severe active rheumatoid arthritis
CTR20200016Phase 3Active
- Sponsor
- Hualan Ankang Biotechnology
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of adalimumab, anjianning in rheumatoid arthritis (RA), sponsored by Hualan Ankang Biotechnology. Started Jul 2020; status: active.
02
Drugs
adalimumabanjianning
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20200016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200016.